4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof

Abstract

The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.

1 - 5 . (canceled) 
     
     
         6 . A fluorescent compound represented by Formula I-B: 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein:
 X 1  and X 2  are each independently O, S, Se, or C(C 1-4  alkyl) 2 ; 
 W 1  and W 2  are a benzo, naphtha, or pyridyl ring; 
 R 1  and R 2  are independently hydrogen or —C 1 -C 10  alkyl optionally substituted with one or two substituents independently selected from the group consisting of halogen, —SO 3 H, —SO 3   − , —COOH, —CO 2   − , and —OH; 
 R 5  and R 7  are each independently hydrogen or —C 1 -C 22  alkylene-X 3 ; 
 R 3 , R 4 , R 13  and R 14  are each independently hydrogen, —C 1 -C 22  alkylene-X 3 , —SO 3 H, —SO 3   − , —SO 2 N(R 12 )-alkylene-X 3 , halogen, or —NO 2 ; 
 X 3  represents independently for each occurrence H, halogen, —CH 3 , —SO 3 H, —SO 3   − , —COOH, —CO 2   − , —NCS, —NCO, N-hydroxysuccinimidyl ester, N-hydroxysulfosuccinimidyl ester, —OH, —SH, maleimide, phthalimide, —NHCO—(CH 2 ) m -(halogen), —CONHNH 2 , —CN, —NH 2 , —NO 2 , —CON(H)R 12 , alkynyl, —N 3 , a polyethyl glycol, optionally substituted aryl, or optionally substituted heterocyclyl; 
 R 9  and R 10  are H, halogen, or alkyl, or R 1  and R 9  or R 2  and R 10  are taken together with their interconnecting atoms to form a 5-, 6- or 7-membered ring; 
 R 11  is —COOH, —CN, halogen, —NO 2 , —C(O)-haloalkyl, haloalkyl, —COOR 15 , —CON(H)R 15 , or —CO(CH 2 ) n R 15 ; 
 R 12  represents independently for each occurrence hydrogen or alkyl; 
 R 15  is H, —COOH, —SO 3 H, —NH 2 , —SH, alkyl, or aryl optionally substituted with X 3  and/or a polyethylene glycol; 
 m represents independently for each occurrence 0, 1, 2, 3, or 4; and 
 n represents independently for each occurrence 1-10. 
 
     
     
         7 . The compound of any  claim 6 , wherein R 5  is —C 1 -C 22  alkylene-X 3 , and R 7  is hydrogen. 
     
     
         8 . The compound of  claim 6 , wherein R 5  is —C 2 -C 8  alkylene-X 3 , and R 7  is hydrogen. 
     
     
         9 . The compound of  claim 6 , wherein R 5  is —C 2 -C 8  alkylene substituted by —SO 3 H, —SO 3   − , or —COOH, and R 7  is hydrogen. 
     
     
         10 - 11 . 
     
     
         12 . The compound of  claim 6 , wherein X 1  and X 2  are C(CH 3 ) 2 . 
     
     
         13 . The compound of  claim 6 , wherein W 1  and W 2  are a benzo ring. 
     
     
         14 . The compound of  claim 6 , wherein W 1  and W 2  are a naptha ring. 
     
     
         15 . The compound of  claim 6 , wherein R 1  and R 2  are independently —C 1 -C 10  alkyl optionally substituted with —SO 3 H or —SO 3   − . 
     
     
         16 . The compound of  claim 6 , wherein R 1  and R 2  are independently C 1 -C 6  alkyl. 
     
     
         17 . The compound of  claim 6 , wherein R 3 , R 4 , R 13  and R 14  are each independently H, —SO 3 H, or —SO 3 . 
     
     
         18 . The compound of  claim 6 , wherein R 7  is hydrogen. 
     
     
         19 . The compound of  claim 6 , wherein R 9  and R 10  are hydrogen. 
     
     
         20 . A conjugate compound formed by reaction of a biological molecule with a compound of  claim 6 . 
     
     
         21 . A conjugate compound that is a compound of  claim 6  further substituted with 1, 2, or 3 -L-BM groups; wherein L is a bond or a linker, and -BM is a radical of a biological molecule. 
     
     
         22 . A pharmaceutical composition comprising a compound of  claim 6  and a pharmaceutically acceptable excipient. 
     
     
         23 - 49 . (canceled) 
     
     
         50 . A method of in vivo imaging, the method comprising:
 a. administering to a subject an agent comprising a compound of  claim 6 ;   b. allowing the agent to distribute within the subject; and   c. detecting a signal emitted by the agent.   
     
     
         51 . A method of in vivo optical imaging, the method comprising:
 a. administering to a subject an agent comprising a compound of  claim 6 , wherein the agent comprises a fluorochrome;   b. allowing the agent to distribute within the subject;   c. exposing the subject to light of a wavelength absorbable by the fluorochrome; and   d. detecting a signal emitted by the agent.   
     
     
         52 - 61 . (canceled) 
     
     
         62 . The method of  claim 51 , wherein, in step (a), cells labeled with the fluorochrome are administered to the subject. 
     
     
         63 . (canceled) 
     
     
         64 . A method of treating a disease in a subject comprising administering to a subject, either systemically or locally, an agent comprising a compound of any one of  claim 6 , wherein the agent comprises a radiolabel that localizes in an area of the disease and delivers an effective dose of radiation. 
     
     
         65 . An in vitro imaging method, the method comprising:
 a. contacting a sample with an agent comprising a compound of  claim 6 ;   b. allowing the agent to bind to a biological target;   c. optionally removing unbound agent; and   d. detecting a signal emitted from the agent thereby to determine whether the agent has been activated by or bound to the biological target.   
     
     
         66 . (canceled)